

November 10, 2010

Tesla Motors Inc.

Solid Quarter. Progress on Track.

Tesla delivered a solid quarter. Revenues and EPS were above our estimates and above consensus, but given the early stage of the company, they don't matter much. More importantly, Model S appears on track and we saw no cause for concern.

Highlights:

- ~400 new Model S reservations in the quarter bring the total to over 3,000 – still on track to pre-sell the first six months of production.
- Model S Alpha build in progress with assembly on track for YE2010 – consistent with earlier targets.
- Model S supplier sourcing on track – will be nearly 100% complete by YE2010.
- Developing custom battery chemistries with Panasonic to reduce cost and improve performance in autos.
- 151 Roadsters sold. Approx 50% in US.
- 30% of US Roadster sales on lease.

Executing well. Tesla is controlling what it can – the quality and timing of Model S deliveries – still set for mid-2012. On the call, management noted some new design features such as the panoramic roof, which they are designing in house. They are leaving ~12 months from the Alpha build at YE2010 to the final design to ensure that “they get all the nuances just right.”

What's next? Management alluded to possible partnerships with other OEMs, but wants to ensure that any partnership would be a good use of Tesla's limited resources and recognizes that distractions could increase risks to the Model S timetable. The IPO lockup expires December 27, 2010, expanding the potential free float from ~15% today to ~55%.

Morgan Stanley & Co. Incorporated **Joshua Paradise**
Joshua.Paradise@morganstanley.com
+1 212 761 4014

Ravi Shanker
Ravi.Shanker@morganstanley.com
+1 212 761 6350

Smittipon Srethapramote
Smittipon.Srethapramote@morganstanley.com
+1 212 761 3914

Timothy Radcliff
Timothy.Radcliff@morganstanley.com
+1 212 761 4139

Key Ratios and Statistics

Reuters: TSLA.O Bloomberg: TSLA US
Clean Tech / United States of America

Shr price, close (Nov 9, 2010)	\$24.63
Mkt cap, curr (mm)	\$2,298
52-Week Range	\$30.42-14.98

Fiscal Year ending	12/09	12/10e	12/11e	12/12e
ModelWare EPS (\$)	(7.96)	(3.12)	(2.25)	(1.44)
EPS (\$)**	(7.96)	(2.84)	(2.12)	(1.31)
Consensus EPS (\$)\$	(1.59)	(2.57)	(1.89)	(1.22)
EV/rev	3.7	19.8	16.9	4.4
Revenue, net (\$mm)	112	110	148	627
Gross margin (%)	8.5	22.7	21.6	11.9
EBITDA margin (%)	(40.2)	(124.8)	(122.9)	(11.7)
Rev hist grth, y/y (%)	-	(1.5)	34.7	322.1

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework (please see explanation later in this note).
\$ = Consensus data is provided by FactSet Estimates.
** = Based on consensus methodology
e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.


For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

November 10, 2010

Tesla Motors Inc.

Risk-Reward Snapshot: Tesla Motors (TSLA, \$24.63, Equal-weight)

Risk-Reward View: Continued Volatility Is Likely



Source: FactSet, Morgan Stanley Research estimates

Valuation Methodology: We apply multiples of 12x EV/EBITDA and 2.1x EV/sales to our 2014 bull, bear, and base case forecasts, and discount the equity value at 15%. Our comp group is 80% clean tech and EV value chain and 20% traditional auto companies.

We also use a DCF analysis with an 11.3% WACC, 15% cost of equity, and 4% terminal growth.

Bull Case \$35	2014e sales = \$2.6 billion 2014e EBITDA = \$463 million	The future of the auto industry. Tesla delivers the Model S on time (2Q12) and on budget with performance that rivals gasoline-powered luxury sedans. EV adoption takes off. EBITDA margins are 15-18%. OEM partnerships add powertrain volumes.
Base Case \$19	2014e sales = \$1.9 billion 2014e EBITDA = \$161 million	Solid execution and EV demand. Model S deliveries start in 3Q12 and reach 20K per year in 2014. Slower ramp and modest cost overruns result in negative EPS until 2014. EBITDA margins are 7-9%. Powertrain sales a minor contributor.
Bear Case \$10	2014e sales = \$461 million 2014e EBITDA = \$(26 million)	Delays, cost overruns, lower demand. A lot can go wrong in a product launch, especially with new manufacturing. We model a slight delay and lower Model S demand of 5,000 units per year. The company would likely need to raise additional capital to scale production.

Key Assumptions for Bull, Bear, and Base Cases

		Bear	Base	Bull
Gross Margin	2012	9.9%	12.0%	13.8%
	2013	9.3%	15.0%	23.5%
	2014	16.5%	20.7%	24.5%
EBIT Margin	2012	NM	NM	NM
	2013	NM	NM	13.7%
	2014	NM	4.7%	15.3%
Model S Volumes	2012	2,000	5,500	7,000
	2013	5,000	15,000	20,000
	2014	5,000	20,000	26,000

Source: Morgan Stanley Research estimates

Why Equal-weight?

- The opportunity in electric vehicles is potentially enormous, but so is the challenge of getting the Model S on the road on time and on budget. At \$24.63, we think the stock fairly reflects the upside and downside potential. Our \$19 base case is based on discounted equity-based multiples of EV/sales and EV/EBITDA and a DCF and reflects uncertain demand for electric vehicles (EVs), increasing competition from OEMs, and execution risk.

Key Value Drivers

- **Model S pre-orders** — the best indicator of demand.
- **Additional or larger OEM partnerships** would add scale, top line growth, and offer further proof of Tesla's technology leadership.
- **EV adoption and subsidies.** Competitors' EVs will launch before the Model S. Strong sales and/or higher government support are positive.

Potential Catalysts

- Expansion of Daimler or Toyota plans or new OEM partnerships.
- Model S — final prototype on factory tools.
- Accelerating Model S reservations.

What Could Make Us Overweight

- Higher Model S pre-orders.
- Increased government subsidies.
- Lower risk of Model S delays.
- Additional and/or larger OEM partnerships.
- More attractive valuation.

...or Underweight

- Significant Model S delays.
- Management turnover in manufacturing, engineering, technology, or design.

November 10, 2010

Tesla Motors Inc.

Exhibit 1

Base Case Quarterly Assumptions

	2009A				2010E				2011E				2012E				2013E			
	Mar-09	Jun-09	Sep-09	Dec-09	Mar-10	Jun-10	Sep-10	Dec-10	Mar-11	Jun-11	Sep-11	Dec-11	Mar-12	Jun-12	Sep-12	Dec-12	Mar-13	Jun-13	Sep-13	Dec-13
Volumes																				
Model S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	3,500	3,750	3,750	3,750	3,750
Roadster	182	200	324	134	126	141	151	155	150	150	150	150	150	150	100	98	-	-	500	300
Next Gen Vehicle	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Vehicles	182	200	324	134	126	141	151	155	150	150	150	150	150	150	2,100	3,598	3,750	3,750	4,250	4,050
Powertrains	-	-	-	-	105	200	240	340	450	650	700	770	800	800	800	800	875	875	875	875
Powertrain ASP (\$)	0.0k	0.0k	0.0k	0.0k	25.9k	24.1k	21.3k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k
Gross Margins																				
Model S	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	8.2%	8.2%	8.4%	12.2%	15.5%	17.8%
Roadster	(9.8%)	7.8%	16.9%	9.6%	17.7%	20.0%	17.0%	18.3%	17.7%	19.6%	21.5%	23.3%	23.3%	23.3%	23.2%	23.2%	0.0%	0.0%	29.8%	28.8%
Powertrain	NM	NM	NM	NM	23.7%	15.0%	18.8%	18.8%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%
Total	NM	7.8%	16.9%	9.6%	18.5%	22.2%	30.0%	18.5%	19.8%	21.1%	22.0%	22.9%	22.9%	22.9%	10.8%	9.8%	9.5%	12.9%	17.6%	19.0%
Roadster Leasing (as % of Total Vehicles Sold)	0.0%	0.0%	0.0%	0.0%	0.0%	10.0%	18.0%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

Exhibit 2

Base Case Annual Assumptions

	Fiscal Year													
	2007A	2008A	2009A	2010E	2011E	2012E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Volumes														
Model S	-	-	-	-	-	5,500	15,000	20,000	23,000	26,450	30,000	30,000	30,000	30,000
Roadster	-	-	-	294	300	249	400	400	400	400	400	400	400	400
Next Gen Vehicle	-	-	-	-	-	-	-	-	-	-	25,000	31,250	39,063	48,828
Total Vehicles	-	-	-	294	300	5,749	15,400	20,400	23,400	26,850	55,400	61,650	69,463	79,228
Powertrains	-	-	-	885	2,570	3,200	3,500	3,500	4,200	5,000	5,000	5,000	5,000	5,000
Powertrain ASP (\$)	NM	NM	NM	23.9k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k	25.0k
Gross Margins														
Model S		NM	NM	NM	NM	8.2%	13.5%	19.7%	20.8%	19.9%	19.5%	19.5%	19.5%	19.5%
Roadster		NM	NM	18.3%	20.6%	23.3%	27.5%	39.5%	38.0%	38.0%	31.6%	40.3%	31.6%	31.6%
Next Gen Vehicle		NM	NM	NM	NM	NM	NM	15.0%	15.0%	15.0%	16.0%	17.0%	18.0%	19.0%
Powertrain		NM	NM	18.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%	22.5%
Total														
Roadster Leasing (as % of Total Vehicles Sold)				12.6%	22.5%	22.5%	22.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

November 10, 2010
Tesla Motors Inc.

Exhibit 3

Base Case Quarterly Income Statement

\$ millions	2009A				2010E				2011E				2012E				2013E			
	Mar-09	Jun-09	Sep-09	Dec-09	Mar-10	Jun-10	Sep-10	Dec-10	Mar-11	Jun-11	Sep-11	Dec-11	Mar-12	Jun-12	Sep-12	Dec-12	Mar-13	Jun-13	Sep-13	Dec-13
Total Revenues	20.9	26.9	45.5	18.6	20.8	28.4	31.2	29.8	31.0	37.2	39.0	41.3	42.4	42.6	207.2	334.6	339.6	345.5	391.1	375.3
Cost of Revenue	22.9	24.8	37.8	16.8	17.0	22.1	21.9	24.3	24.9	29.4	30.4	31.8	32.7	32.9	184.7	301.6	307.4	301.0	322.3	304.0
Gross Profit	(2.0)	2.1	7.7	1.8	3.9	6.3	9.4	5.5	6.1	7.9	8.6	9.4	9.7	9.7	22.5	32.9	32.2	44.5	68.8	71.3
Gross Profit Margin	NM	7.8%	16.9%	9.6%	18.5%	22.2%	30.0%	18.5%	19.8%	21.1%	22.0%	22.9%	22.9%	22.9%	10.8%	9.8%	9.5%	12.9%	17.6%	19.0%
Expenses																				
Research and Development	7.9	1.9	1.3	8.1	13.3	14.9	25.4	37.0	37.5	37.5	37.5	37.5	22.3	22.3	22.3	22.3	20.0	15.0	15.0	10.0
Sales and Marketing	-	-	-	-	6.0	7.0	9.0	9.0	11.0	11.0	11.0	11.0	15.3	15.3	15.3	15.3	27.8	27.8	27.8	27.8
General and Administrative	6.6	8.2	10.7	16.6	7.2	9.7	8.9	8.0	8.3	8.3	8.3	8.3	8.8	8.8	8.8	8.8	8.8	8.8	8.8	8.8
Stock-based Compensation	-	-	-	-	3.4	6.1	3.8	5.0	3.9	3.9	3.9	3.9	4.0	4.0	4.0	4.0	4.6	4.2	4.2	3.8
Total Expenses	14.5	10.2	12.0	24.7	29.9	37.7	47.2	59.0	60.7	60.7	60.7	60.7	50.3	50.3	50.3	50.3	61.1	55.7	55.7	50.3
Operating (Loss) Income	(16.6)	(8.1)	(4.3)	(22.9)	(26.0)	(31.4)	(37.8)	(53.5)	(54.6)	(52.8)	(52.1)	(51.3)	(40.6)	(40.5)	(27.8)	(17.3)	(28.9)	(11.1)	13.2	21.1
Operating Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	3.4%	5.6%
EBITDA (excl. SBC)	(16.6)	(8.1)	0.7	(21.0)	(20.5)	(22.8)	(30.9)	(45.1)	(46.3)	(42.4)	(40.0)	(37.9)	(25.4)	(23.2)	(9.7)	0.8	(10.5)	7.8	32.7	41.0
EBITDA Margin	NM	NM	1.6%	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	0.2%	NM	2.3%	8.4%	10.9%
Interest Expense, net	(1.4)	(1.1)	0.0	0.0	(0.2)	(0.4)	(0.3)	(0.4)	(0.5)	(1.2)	(1.9)	(2.6)	(3.2)	(3.8)	(4.2)	(4.5)	(4.5)	(4.5)	(4.5)	(4.5)
Other Income (Expense), net	2.0	(1.7)	(0.6)	(1.1)	(3.2)	(6.7)	3.3	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Other Income (Expense)	0.6	(2.8)	(0.5)	(1.1)	(3.4)	(7.1)	3.0	(0.4)	(0.5)	(1.2)	(1.9)	(2.6)	(3.2)	(3.8)	(4.2)	(4.5)	(4.5)	(4.5)	(4.5)	(4.5)
Pre-tax Income	(16.0)	(10.9)	(4.8)	(24.0)	(29.4)	(38.5)	(34.9)	(53.9)	(55.0)	(54.0)	(54.0)	(53.8)	(43.8)	(44.3)	(32.0)	(21.8)	(33.4)	(15.7)	8.7	16.6
Pre-tax margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	2.2%	4.4%
Taxes, GAAP	0.0	0.0	(0.2)	0.2	0.1	0.0	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax Impact of One-Time Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes, Recurring	0.0	0.0	(0.2)	0.2	0.1	0.0	0.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Effective Tax Rate	(0.0%)	(0.1%)	4.5%	(1.0%)	(0.4%)	(0.0%)	(0.2%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Recurring Net Income	(16.0)	(10.9)	(4.6)	(24.2)	(29.5)	(38.5)	(34.9)	(53.9)	(55.0)	(54.0)	(54.0)	(53.8)	(43.8)	(44.3)	(32.0)	(21.8)	(33.4)	(15.7)	8.7	16.6
Recurring NI Margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	2.2%	4.4%
Cumulative Effect of Accounting Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
One-Time Charges/Adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(16.0)	(10.9)	(4.6)	(24.2)	(29.5)	(38.5)	(34.9)	(53.9)	(55.0)	(54.0)	(54.0)	(53.8)	(43.8)	(44.3)	(32.0)	(21.8)	(33.4)	(15.7)	8.7	16.6
GAAP EPS									(\$0.38)	(\$0.57)	(\$0.56)	(\$0.55)	(\$0.45)	(\$0.45)	(\$0.32)	(\$0.22)	(\$0.33)	(\$0.16)	\$0.08	\$0.14
Adjusted EPS									(\$0.35)	(\$0.53)	(\$0.53)	(\$0.52)	(\$0.42)	(\$0.42)	(\$0.29)	(\$0.19)	(\$0.30)	(\$0.12)	\$0.10	\$0.17

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

November 10, 2010

Tesla Motors Inc.

Exhibit 4

Base Case Annual Income Statement

\$ millions	Fiscal Year													
	2007A	2008A	2009A	2010E	2011E	2012E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Total Revenues	0.1	14.7	111.9	110.2	148.5	626.7	1,451.5	1,879.7	2,163.0	2,436.9	3,766.5	4,015.9	4,293.1	4,693.5
Cost of Revenue	0.0	15.9	102.4	85.2	116.5	551.9	1,234.7	1,487.4	1,694.7	1,931.2	3,055.3	3,241.6	3,465.5	3,773.8
Gross Profit	0.1	(1.1)	9.5	25.0	32.0	74.8	216.9	392.3	468.4	505.8	711.3	774.3	827.5	919.6
Gross Profit Margin	87.7%	NM	8.5%	22.7%	21.6%	11.9%	14.9%	20.9%	21.7%	20.8%	18.9%	19.3%	19.3%	19.6%
Expenses														
Research and Development	62.7	53.6	19.3	90.6	150.0	89.0	60.0	80.0	85.6	91.6	98.0	104.9	112.2	120.1
Sales and Marketing	-	-	-	31.0	44.0	61.0	111.0	131.6	151.4	170.6	263.7	281.1	300.5	328.5
General and Administrative	17.1	23.4	42.2	33.8	33.0	35.0	35.0	70.5	75.7	85.3	131.8	120.5	128.8	140.8
Stock-based Compensation	0.2	0.4	-	18.3	15.8	16.1	16.7	19.6	19.1	18.3	21.9	18.4	16.7	18.2
Total Expenses	80.0	77.4	61.4	173.7	242.8	201.1	222.7	301.7	331.8	365.8	515.4	524.8	558.3	607.6
Operating (Loss) Income	(79.9)	(78.5)	(51.9)	(148.7)	(210.8)	(126.3)	(5.8)	90.6	136.6	140.0	195.9	249.5	269.3	312.0
Operating Margin	NM	NM	NM	NM	NM	NM	NM	4.8%	6.3%	5.7%	5.2%	6.2%	6.3%	6.6%
EBITDA (excl. SBC)	(76.8)	(73.9)	(45.0)	(119.3)	(166.7)	(57.4)	71.0	166.3	228.1	248.3	316.7	397.0	414.7	470.0
EBITDA Margin	NM	NM	NM	NM	NM	NM	4.9%	8.8%	10.5%	10.2%	8.4%	9.9%	9.7%	10.0%
Interest Expense, net	1.7	(3.2)	(2.4)	(1.3)	(6.1)	(15.7)	(18.1)	(16.5)	(10.4)	(1.5)	1.2	2.1	3.4	4.6
Other Income (Expense), net	0.1	(1.0)	(1.4)	(6.7)	-	-	-	-	-	-	-	-	-	-
Total Other Income (Expense)	1.9	(4.2)	(3.8)	(8.0)	(6.1)	(15.7)	(18.1)	(16.5)	(10.4)	(1.5)	1.2	2.1	3.4	4.6
Pre-tax Income	(78.0)	(82.7)	(55.7)	(156.7)	(216.9)	(142.0)	(23.9)	74.1	126.2	138.5	197.1	251.6	272.7	316.6
Pre-tax margin	NM	NM	NM	NM	NM	NM	NM	3.9%	5.8%	5.7%	5.2%	6.3%	6.4%	6.7%
Taxes, GAAP	0.1	0.1	0.0	0.2	-	-	-	-	-	-	-	-	62.4	76.0
Tax Impact of One-Time Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Taxes, Recurring	0.1	0.1	0.0	0.2	-	-	-	-	-	-	-	-	62.4	76.0
Effective Tax Rate	(0.1%)	(0.1%)	(0.0%)	(0.1%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	22.9%	24.0%
Recurring Net Income	(78.2)	(82.8)	(55.7)	(156.9)	(216.9)	(142.0)	(23.9)	74.1	126.2	138.5	197.1	251.6	210.3	240.6
Recurring NI Margin	NM	NM	NM	NM	NM	NM	NM	3.9%	5.8%	5.7%	5.2%	6.3%	4.9%	5.1%
Cumulative Effect of Accounting Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-
One-Time Charges/Adjustments	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(78.2)	(82.8)	(55.7)	(156.9)	(216.9)	(142.0)	(23.9)	74.1	126.2	138.5	197.1	251.6	210.3	240.6
GAAP EPS				(\$3.12)	(\$2.25)	(\$1.44)	(\$0.22)	\$0.64	\$1.06	\$1.13	\$1.57	\$1.96	\$1.60	\$1.79
Adjusted EPS				(\$2.84)	(\$2.12)	(\$1.31)	(\$0.10)	\$0.76	\$1.18	\$1.25	\$1.71	\$2.07	\$1.70	\$1.89

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

November 10, 2010
Tesla Motors Inc.

Exhibit 5

Base Case Annual Balance Sheet

\$ millions	Fiscal Year													
	2007A	2008A	2009A	2010E	2011E	2012E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Current Assets														
Cash and cash equivalents	17.2	9.3	69.6	101.3	100.0	44.0	100.0	100.0	100.0	294.9	609.1	1,084.5	1,531.8	2,041.8
Accounts receivable, net	0.1	3.3	3.5	1.6	12.3	12.2	13.5	13.0	15.8	18.7	18.6	18.6	18.3	18.2
Inventories, net	2.1	16.7	23.2	31.7	38.1	360.7	363.4	448.3	510.7	580.4	920.8	976.9	1,044.4	1,134.2
Prepaid expenses and other current assets	2.9	2.2	4.2	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0
Total Current Assets	22.3	31.4	100.6	139.6	155.4	421.9	481.9	566.3	631.6	899.1	1,553.5	2,085.0	2,599.5	3,199.2
Property, Plant and Equipment, net	12.0	18.8	23.5	49.9	161.8	194.9	190.5	268.6	342.9	416.0	492.7	541.0	587.6	637.1
Restricted cash	0.3	1.2	3.6	145.6	145.6	145.6	145.6	145.6	145.6	145.6	145.6	145.6	145.6	145.6
Other assets	0.3	0.3	2.8	20.1	20.1	20.1	20.1	20.1	20.1	20.1	20.1	20.1	20.1	20.1
Total Assets	34.8	51.7	130.4	365.6	508.7	817.0	877.8	1,029.5	1,160.5	1,492.7	2,223.8	2,791.8	3,352.8	4,002.1
Current Liabilities														
Accounts payable	5.4	14.2	15.1	23.7	31.1	295.1	297.3	366.8	417.9	474.9	753.3	799.3	854.5	928.0
Accrued liabilities	8.5	11.1	14.5	9.0	10.4	16.6	57.7	111.7	164.4	216.8	307.4	390.8	470.9	553.9
Deferred development compensation	-	10.2	0.2	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue	-	4.1	1.4	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Capital lease obligations, current portion	0.1	0.3	0.3	-	-	-	-	-	-	-	-	-	-	-
Refundable reservation payments	37.3	48.0	26.0	29.5	33.9	11.9	-	-	-	-	-	-	-	-
Total Current Liabilities	51.3	87.9	57.5	63.2	76.4	324.6	356.1	479.4	583.3	692.7	1,061.7	1,191.1	1,326.4	1,482.9
Convertible preferred stock warrant liability	0.2	2.1	1.7	-	-	-	-	-	-	-	-	-	-	-
Capital lease obligations, less current portion	0.0	0.9	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
Convertible notes payable	-	54.5	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue, less current portion	-	-	1.2	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities	-	4.8	3.5	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total Convertible Preferred Stock	101.2	101.2	319.2	-	-	-	-	-	-	-	-	-	-	-
DOE Loan	-	-	-	64.2	339.4	465.0	429.8	276.8	55.6	-	-	-	-	-
Total Long-Term Liabilities	101.4	163.5	326.5	67.0	342.2	467.9	432.6	279.7	58.4	2.9	2.9	2.9	2.9	2.9
Total Liabilities	152.7	251.4	383.9	130.2	418.7	792.5	788.7	759.1	641.7	695.6	1,064.6	1,193.9	1,329.3	1,485.7
Stockholders' Equity														
Common stock	0.0	0.0	0.0	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital	4.3	5.2	7.1	634.1	705.5	782.0	870.4	977.6	1,099.8	1,239.7	1,404.7	1,591.7	1,807.1	2,059.3
Retained Earnings	(122.1)	(204.9)	(260.7)	(398.6)	(615.5)	(757.4)	(781.3)	(707.2)	(581.0)	(442.6)	(245.5)	6.1	216.4	457.0
Accumulated other comprehensive loss, net	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total stockholders' equity	(117.8)	(199.7)	(253.5)	235.5	90.0	24.5	89.1	270.4	518.8	797.1	1,159.3	1,597.8	2,023.5	2,516.3
Total Liabilities and Stockholders' Equity	34.8	51.7	130.4	365.6	508.7	817.0	877.8	1,029.5	1,160.5	1,492.7	2,223.8	2,791.8	3,352.8	4,002.1

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

November 10, 2010

Tesla Motors Inc.

Exhibit 6

Base Case Cash Flow Statement

\$ millions	Fiscal Year													
	2007A	2008A	2009A	2010E	2011E	2012E	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E
Operating Activities:														
Net Income	(78.2)	(82.8)	(55.7)	(156.9)	(216.9)	(142.0)	(23.9)	74.1	126.2	138.5	197.1	251.6	210.3	240.6
Depreciation and Amortization	2.9	4.2	6.9	11.1	28.3	52.8	60.1	56.0	72.4	90.0	98.9	129.1	128.7	139.8
Change in fair value of convertible preferred stock warrant liability	(0.0)	2.8	1.1	8.7	-	-	-	-	-	-	-	-	-	-
Gain on extinguishment of convertible notes and warrants	-	(1.2)	(1.5)	-	-	-	-	-	-	-	-	-	-	-
Stock compensation expense	0.2	0.4	1.4	18.3	15.8	16.1	16.7	19.6	19.1	18.3	21.9	18.4	16.7	18.2
Loss on abandonment of fixed assets	2.4	-	0.4	-	-	-	-	-	-	-	-	-	-	-
Inventory write-downs	-	-	1.4	0.4	-	-	-	-	-	-	-	-	-	-
Interest on convertible notes	-	3.7	2.7	-	-	-	-	-	-	-	-	-	-	-
Changes in Current Assets and Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, net	(0.1)	(3.3)	(0.2)	1.9	(10.7)	0.1	(1.3)	0.5	(2.8)	(2.9)	0.1	0.1	0.3	0.1
Inventories	(2.1)	(14.5)	(7.9)	(8.8)	(6.4)	(322.6)	(2.8)	(84.8)	(62.5)	(69.7)	(340.4)	(56.2)	(67.5)	(89.8)
Prepaid expenses and other current assets	(1.9)	0.8	(2.0)	0.9	-	-	-	-	-	-	-	-	-	-
Other assets	(0.1)	0.0	(0.4)	(17.2)	-	-	-	-	-	-	-	-	-	-
Accounts payable	0.5	8.8	0.9	4.1	7.4	263.9	2.3	69.4	51.1	57.0	278.5	46.0	55.2	73.5
Accrued liabilities	7.6	2.6	3.4	(3.9)	1.4	6.3	41.1	53.9	52.8	52.4	90.5	83.4	80.1	83.0
Other long-term liabilities	-	1.2	2.2	(1.5)	-	-	-	-	-	-	-	-	-	-
Deferred development compensation	-	10.2	(10.0)	(0.2)	-	-	-	-	-	-	-	-	-	-
Deferred revenue	-	4.1	(1.5)	(1.6)	-	-	-	-	-	-	-	-	-	-
Refundable reservation payments	15.2	10.7	(22.0)	3.4	4.5	(22.0)	(11.9)	-	-	-	-	-	-	-
Changes in Current Assets and Liabilities	19.2	20.5	(37.5)	(22.9)	(3.8)	(74.3)	27.4	39.0	38.6	36.8	28.8	73.3	68.1	66.8
Net Cash Flow from Operating Activities	(53.5)	(52.4)	(80.8)	(141.3)	(176.5)	(147.4)	80.3	188.7	256.2	283.6	346.7	472.3	423.9	465.4
Investing activities:														
Purchases of property and equipment excluding capital leases	(9.8)	(9.6)	(11.9)	(89.9)	(136.5)	(78.8)	(42.0)	(123.4)	(138.2)	(154.7)	(175.7)	(165.6)	(175.3)	(189.3)
Decrease (increase) in restricted cash	0.0	(1.0)	(2.4)	(96.1)	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities	(9.8)	(10.6)	(14.2)	(194.9)	(155.6)	(94.6)	(60.8)	(123.4)	(138.2)	(154.7)	(175.7)	(165.6)	(175.3)	(189.3)
Financing activities:														
Proceeds from issuance of convertible preferred stock, net of issuance	44.9	-	131.8	-	-	-	-	-	-	-	-	-	-	-
Proceeds from DOE Loan	-	-	-	64.2	275.2	125.6	(35.2)	(152.9)	(221.3)	(55.6)	-	-	-	-
Principal payments on capital leases and other debt	-	(0.2)	(0.3)	(0.2)	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes and warrants	-	54.8	25.5	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Issuance of Common Stock	-	0.0	-	273.8	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options	0.1	0.5	0.5	35.0	55.6	60.4	71.7	87.6	103.2	121.5	143.2	168.6	198.6	234.0
Deferred common stock and loan facility issuance costs	-	-	(2.0)	(3.5)	-	-	-	-	-	-	-	-	-	-
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities	45.0	55.1	155.4	369.2	330.8	186.0	36.5	(65.4)	(118.1)	66.0	143.2	168.6	198.6	234.0
Effect of Exchange Rate Changes														
Cash Restatement	-	-	-	(1.3)	-	-	-	-	-	-	-	-	-	-
Net Change in Cash and Cash Equivalents														
Cash and cash equivalents at beginning of the year	35.4	17.2	9.3	69.6	101.3	100.0	44.0	100.0	100.0	100.0	294.9	609.1	1,084.5	1,531.8
Cash and cash equivalents at end of year	17.2	9.3	69.6	101.3	100.0	44.0	100.0	100.0	100.0	294.9	609.1	1,084.5	1,531.8	2,041.8

Source: Company data, Morgan Stanley Research estimates; E = Morgan Stanley Research estimates

November 10, 2010

Tesla Motors Inc.



Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. Incorporated, and/or Morgan Stanley C.T.V.M. S.A. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. Incorporated, Morgan Stanley C.T.V.M. S.A. and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Joshua Paradise.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict/policies.

Important US Regulatory Disclosures on Subject Companies

As of September 30, 2010, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Cree, Inc., SunPower Corporation.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Tesla Motors Inc..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from First Solar Inc., SunPower Corporation, Tesla Motors Inc..

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Cree, Inc., Energy Conversion Devices, Inc, First Solar Inc., SunPower Corporation, Tesla Motors Inc..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from First Solar Inc., SunPower Corporation.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Cree, Inc., Energy Conversion Devices, Inc, First Solar Inc., SunPower Corporation, Tesla Motors Inc..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: First Solar Inc., SunPower Corporation. Morgan Stanley & Co. Incorporated makes a market in the securities of Cree, Inc., Energy Conversion Devices, Inc, Evergreen Solar Inc, First Solar Inc., SunPower Corporation, Tesla Motors Inc..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of October 31, 2010)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

November 10, 2010

Tesla Motors Inc.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)		
	Count	% of Total	Count	% of Total IBC	% of Rating Category
Overweight/Buy	1122	40%	413	44%	37%
Equal-weight/Hold	1158	41%	411	43%	35%
Not-Rated/Hold	121	4%	22	2%	18%
Underweight/Sell	393	14%	103	11%	26%
Total	2,794		949		

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views


Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Stock Price, Price Target and Rating History (See Rating Definitions)



Stock Rating History: 3/24/10 : NA/I; 8/9/10 : E/I

Price Target History: 8/9/10 : NA

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
 Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —
 Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View
 Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) More Volatile (V) No Rating Available (NA)
 Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of First Solar Inc..

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

The fixed income research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index; or any securities/instruments issued by a company that is 30% or more directly- or indirectly-owned by the government of or a company incorporated in the PRC and traded on an exchange in Hong Kong or Macau, namely SEHK's Red Chip shares, including the component company of the SEHK's China-affiliated Corp Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Morgan Stanley Research is disseminated in Japan by Morgan Stanley MUFG Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by the Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Morgan Stanley Private Wealth Management Limited, authorized and regulated by the Financial Services Authority, also disseminates Morgan Stanley Research in the UK. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc or Morgan Stanley Private Wealth Management representative about the investments concerned. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio

November 10, 2010
Tesla Motors Inc.

management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas

1585 Broadway
New York, NY 10036-8293
United States
Tel: +1 (1) 212 761 4000

Europe

20 Bank Street, Canary Wharf
London E14 4AD
United Kingdom
Tel: +44 (0) 20 7 425 8000

Japan

4-20-3 Ebisu, Shibuya-ku
Tokyo 150-6008
Japan
Tel: +81 (0) 3 5424 5000

Asia/Pacific

1 Austin Road West
Kowloon
Hong Kong
Tel: +852 2848 5200

Industry Coverage: Clean Tech

Company (Ticker)	Rating (as of)	Price* (11/09/2010)
Joshua Paradise		
Cree, Inc. (CREE.O)	E (10/20/2010)	\$54.46
Energy Conversion Devices, Inc (ENER.O)	E (11/10/2010)	\$4.86
Tesla Motors Inc. (TSLA.O)	E (08/09/2010)	\$24.63
Smittipon Srethapramote		
Amyris Inc. (AMRS.O)	O (11/08/2010)	\$17.48
Evergreen Solar Inc (ESLR.O)	E (03/24/2010)	\$.93
First Solar Inc. (FSLR.O)	O (03/24/2010)	\$138.62
SunPower Corporation (SPWR.O)	E (10/08/2010)	\$14.05

Stock Ratings are subject to change. Please see latest research for each company.
* Historical prices are not split adjusted.